Derm Cases · Medicine
OSCE — Erythema annulare centrifugum (EAC)
Eight-minute OSCE station on Erythema annulare centrifugum (EAC): focused history, examination priorities, investigations, emergency and definitive management.
On this page
Study tools
Target exams
Brief (to candidate)
You will assess a patient with a presentation consistent with Erythema annulare centrifugum (EAC).
You have 8 minutes to take a focused history, outline examination, investigations, and management including red flags.
Clinical context
Erythema annulare centrifugum (EAC) is a figurate (annular or polycyclic) erythema characterised by slowly expanding, erythematous rings with a pathognomonic TRAILING SCALE — a fine scale located just INSIDE the advancing inner edge. It is a reactive type IV hypersensitivity reaction to a distant antigen, most often a dermatophyte (tinea) producing an id reaction, but also drugs, infections, foods, and rarely underlying malignancy (paraneoplastic 'PEACE'). Histology shows the classic 'coat-sleeve' tight perivascular lymphocytic infiltrate. Management is to identify and treat the underlying trigger; EAC is self-limiting but runs a chronic, relapsing course over weeks to months.
[3]Candidate tasks
- Clarify onset, severity, associated features, and red-flag symptoms.
- State focused examination priorities.
- List first-line investigations and any named score/criteria.
- Give immediate resuscitation steps.
- Outline definitive management with doses/routes where standard.
- Name complications and disposition (ward / HDU / theatre / discharge safety-net).
- Mention one special-population modifier (pregnancy, child, elderly, CKD).
Examiner checklist
| Domain | Pass behaviours |
|---|---|
| Definition | Correct working diagnosis language |
| Assessment | Focused, prioritised, red flags sought |
| Investigations | Appropriate first-line + interpretation |
| Emergency care | ABC / time-critical actions first |
| Definitive care | Specific drugs/procedures, not generic phrases |
| Safety | EAC unresponsive to treatment of an obvious trigger, or with systemic symptoms ( |
| Communication | Clear plan and safety-netting |
Model outline
Lead with the working diagnosis and life threats. Resuscitate before definitive tests when unstable. Use guideline-standard therapy with named agents and doses. Document escalation criteria and follow-up. A safe candidate is specific, structured, and never delays critical care for non-urgent imaging.[1]
References4ShowHide
- [1]Al Hammadi A, Asai Y, Patt ML, et al. Erythema annulare centrifugum secondary to treatment with finasteride J Drugs Dermatol, 2007.PMID 17668547
- [2]Chiang CH, Lai FJ Pregnancy-associated erythema annulare centrifugum J Formos Med Assoc, 2015.PMID 24548620
- [3]Chodkiewicz HM, Cohen PR, et al. Paraneoplastic erythema annulare centrifugum eruption: PEACE Am J Clin Dermatol, 2012.PMID 22320680
- [4]Chou WT, Tsai TF Recurrent erythema annulare centrifugum during ustekinumab treatment in a psoriatic patient Acta Derm Venereol, 2013.PMID 22983014